Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

By Vilar Lucio  

Pituitary, Vol. 14, Iss. 2, 2011-06 ,pp. : 148-156

Springer Publishing Company

Access to resources Recommend Favorite

Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review

By Behan L.  

Pituitary, Vol. 14, Iss. 4, 2011-12 ,pp. : 362-366

Springer Publishing Company

Access to resources Recommend Favorite

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

By lvarez Claudio   Alonso-Muriel Isabel   Garca Gabriela   Crespo Juana   Bellver Jos   Simn Carlos   Pellicer Antonio  

Human Reproduction, Vol. 22, Iss. 12, 2007-12 ,pp. : 3210-3214

Oxford University Press

Access to resources Recommend Favorite

Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma

By Alberiche Ruano M.  

Pituitary, Vol. 13, Iss. 4, 2010-12 ,pp. : 380-382

Springer Publishing Company

Access to resources Recommend Favorite

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

By Neff Lisa   Weil Michelle   Cole Alan   Hedges Thomas   Shucart William   Lawrence Donald   Zhu Jay-Jiguang   Tischler Arthur   Lechan Ronald  

Pituitary, Vol. 10, Iss. 1, 2007-03 ,pp. : 81-86

Springer Publishing Company

Access to resources Recommend Favorite